AIM: Fatty acid-binding protein 4 (FABP4) plays an important role in maintaining glucose and lipid homeostasis. The aim of this study was to find new inhibitors of FABP4 for the treatment of type 2 diabetes. METHODS: Human FABP4 protein was expressed, and its inhibitors were detected in 1,8-ANS displacement assay. The effect of the inhibitor on lipolysis activity was examined in mouse 3T3-L1 preadipocytes. The db/db mice were used to evaluate the anti-diabetic activity of the inhibitor. Molecular docking and site-directed mutagenesis studies were carried out to explore the binding mode between the inhibitor and FABP4. RESULTS: From 232 compounds tested, benzbromarone (BBR), an old uricosuric drug, was discovered to be the best inhibitor of FABP4 with an IC50 value of 14.8 μmol/L. Furthermore, BBR (25 μmol/L) significantly inhibited forskolin-stimulated lipolysis in 3T3-L1 cells. Oral administration of BBR (25 or 50 mg/kg, for 4 weeks) dose-dependently reduced the blood glucose level and improved glucose tolerance and insulin resistance in db/db mice. Molecular docking revealed that the residues Ser55, Asp76, and Arg126 of FABP4 formed important interactions with BBR, which was confirmed by site-directed mutagenesis studies. CONCLUSION: BBR is an inhibitor of FABP4 and a potential drug candidate for the treatment of type 2 diabetes and atherosclerosis.
AIM: Fatty acid-binding protein 4 (FABP4) plays an important role in maintaining glucose and lipid homeostasis. The aim of this study was to find new inhibitors of FABP4 for the treatment of type 2 diabetes. METHODS:HumanFABP4 protein was expressed, and its inhibitors were detected in 1,8-ANS displacement assay. The effect of the inhibitor on lipolysis activity was examined in mouse 3T3-L1 preadipocytes. The db/db mice were used to evaluate the anti-diabetic activity of the inhibitor. Molecular docking and site-directed mutagenesis studies were carried out to explore the binding mode between the inhibitor and FABP4. RESULTS: From 232 compounds tested, benzbromarone (BBR), an old uricosuric drug, was discovered to be the best inhibitor of FABP4 with an IC50 value of 14.8 μmol/L. Furthermore, BBR (25 μmol/L) significantly inhibited forskolin-stimulated lipolysis in 3T3-L1 cells. Oral administration of BBR (25 or 50 mg/kg, for 4 weeks) dose-dependently reduced the blood glucose level and improved glucose tolerance and insulin resistance in db/db mice. Molecular docking revealed that the residues Ser55, Asp76, and Arg126 of FABP4 formed important interactions with BBR, which was confirmed by site-directed mutagenesis studies. CONCLUSION:BBR is an inhibitor of FABP4 and a potential drug candidate for the treatment of type 2 diabetes and atherosclerosis.
Authors: M C Carmona; K Louche; M Nibbelink; B Prunet; A Bross; M Desbazeille; C Dacquet; P Renard; L Casteilla; L Pénicaud Journal: Int J Obes (Lond) Date: 2005-07 Impact factor: 5.095
Authors: Tjeerd Barf; Fredrik Lehmann; Kristin Hammer; Saba Haile; Eva Axen; Carmen Medina; Jonas Uppenberg; Stefan Svensson; Lena Rondahl; Thomas Lundbäck Journal: Bioorg Med Chem Lett Date: 2009-01-30 Impact factor: 2.823
Authors: Richard Sulsky; David R Magnin; Yanting Huang; Ligaya Simpkins; Prakash Taunk; Manorama Patel; Yeheng Zhu; Terry R Stouch; Donna Bassolino-Klimas; Rex Parker; Thomas Harrity; Robert Stoffel; David S Taylor; Thomas B Lavoie; Kevin Kish; Bruce L Jacobson; Steven Sheriff; Leonard P Adam; William R Ewing; Jeffrey A Robl Journal: Bioorg Med Chem Lett Date: 2006-12-21 Impact factor: 2.823
Authors: Laura C López; Olga Varea; Susanna Navarro; José A Carrodeguas; Natalia Sanchez de Groot; Salvador Ventura; Javier Sancho Journal: Int J Mol Sci Date: 2016-06-18 Impact factor: 5.923